Who is sponsoring NCT04992728?

NCT04992728 is sponsored by University of California, San Diego.

What drugs are being tested in NCT04992728?

Interventions in NCT04992728: Restricted Spectrum Magnetic Resonance Imagining.

What condition does NCT04992728 study?

NCT04992728 studies Prostate Cancer.

Is NCT04992728 still recruiting?

NCT04992728 is currently recruiting now. Last updated 6 February 2025.

Last reviewed 2025-02-06 · How we verify

NCT04992728

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI

Recruiting now Last updated 6 February 2025

What this trial tests

trial testing Restricted Spectrum Magnetic Resonance Imagining in Prostate Cancer in 100 participants. Currently enrolling.

Timeline

2 November 2021

Primary endpoint
1 November 2025

1 November 2026

Quick facts

Lead sponsor	University of California, San Diego
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100
Start date	2 November 2021
Primary completion	1 November 2025
Estimated completion	1 November 2026
Sites	1 location across United States

Drugs / interventions tested

Restricted Spectrum Magnetic Resonance Imagining

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University of California, San Diego

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single-center study will enroll 40 male participants to complete 2 diffusion magnetic resonance images within 30 days of each other.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Systematic effects of patient factors and scanner/protocol factors on a Restriction Spectrum Imaging (RSI) quantitative MRI biomarker for prostate cancer.
Do DD, Domingo MR, Conlin CC, Matthews I, et al · · 2026 · PMID 41992373 · DOI 10.1186/s40644-026-01032-w
The role of diffusion-weighted MRI in biological image-guided radiation therapy: a roadmap.
Deng J, Tadimalla S, Seibert TM, Gach HM, et al · · 2026 · PMID 41956106 · DOI 10.1088/1361-6560/ae5d80

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University of California, San Diego trials

Trials by the same sponsor.

NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04992728 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 6 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04992728.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing